HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 10, September 2017 – Cardiovascular diseases       » Test strips for cancer detection get upgraded with nanoparticle bling       » Smart nano-pesticide to combat soil and water contamination       » China plans to launch "brain project" by year end       » UNAIDS encourages Chinese to produce drugs for Africa       » Korea-Singapore Healthcare Incubator to support Korean firms in Singapore and Southeast Asia       » Nanomaterial wrap for improved tissue imaging      
BIOBOARD - EUROPE
Curetis obtains key patent for UnyveroTM technology
Curetis AG, a developer of next-level molecular diagnostic solutions, has been granted a core technology patent by IP Australia, the Australian patent office, for its UnyveroTM platform technology. The patent, "Reaction Vessel for PCR Device and Method of Performing PCR," is the first of several core technology patents filed by Curetis. Its claims cover PCR chamber vessels allowing the integrated amplification and detection of DNA sequences. Curetis has submitted patent applications covering this technology in other key regions, including Europe, the U.S. and Japan. The Company expects these additional patents to be granted in the near future.

The CE-marked UnyveroTM System is a versatile hardware platform for the detection of a broad panel of bacteria, fungi and antibiotic resistances from a single sample in one run.

"We are extremely pleased that the patent was granted without any restrictions in scope, as it covers a critical and indispensable aspect of our Unyvero platform," said Dr. Gerd Luedke, Director Bio-Assay Development of Curetis. "This decision supports all of our claims around a unique and proprietary way of combining end-point PCR with an array-based detection in a single reaction vessel - something that has never been done before. It affords Unyvero certain competitive advantages in terms of multiplexing capabilities and cost of goods at a very high number of analytes."

"Our Unyvero Solution offers a highly attractive alternative to real-time PCR because it integrates both amplification and detection," said Oliver Schacht, CEO of Curetis. "Unyvero allows for superior multiplexing as compared to conventional PCR devices and methods without increasing the risk of sample cross-contamination."

Click here for the complete issue.

NEWS CRUNCH  
news $1.7 million awarded to Australian biomedical researchers through philanthropic Ramaciotti Foundations
news Genetically boosting the nutritional value of corn could benefit millions
news Inhibitor Pariet obtained approval of additional dosage in Japan for maintenance therapy of proton pump inhibitor resistant reflux esophagitis
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetes: The Big Picture
May:
The Piece of Your Mind - Brain Health/Science
June:
Advocacies in Support of Rare Disease Patients
July:
Food Science & Technology
August:
Eye – the Window to your Soul
September:
Infectious Diseases
October:
A change of heart — Cardiovascular diseases
November:
Diseases threatening our Children
December:
Skin Diseases/Allergic Reactions
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy